Goldman Sachs initiated coverage of United Therapeutics Corporation with a 'Sell' rating and set a price target of $321, which is 34% below its current trading price of $489.42. The bearish outlook is influenced by recent insider selling, institutional stake reductions, and the stock trading below key moving averages. However, some investors remain optimistic due to the company's strong Tyvaso drug franchise and potential upcoming drug approvals that could boost growth. The stock's current price-to-earnings ratio is 17.80, and technical indicators suggest downward momentum in the near term.
United Therapeutics stock is the subject of this update. For readers following the health sector, here is Pluang's market snapshot as of Sep 24, 2026 19:31 WIB: out of 100 priced US health stocks, 40 rose and 55 fell. Notable movers include Heron Therapeutics Inc (HRTX) at USD 0.30 with a 3.06% gain and BioNano Genomics Inc (BNGO) at USD 1.74 with a 2.35% gain, while InMode Ltd (INMD) declined 1.83% to USD 13.93.
Vecima Networks reported strong quarterly results with revenue of $64.04 million, surpassing the $55.69 million estimate, and earnings per share of $0.15, beating the $0.14 forecast. The company, a broadband technology provider for cable and fiber op...
Bernstein upgraded Dollar General to "Outperform" due to its strategic initiatives targeting budget shoppers and expanding seasonal product offerings, especially affordable toys. The company is also growing its DG Media Network, which generates signi...
TD SYNNEX reported quarterly earnings per share of $5.68, surpassing analyst estimates of $4.70 by 22.41%, and revenue of $21.56 billion, beating estimates by 14.81%. This strong performance reflects a 37.7% revenue increase year-over-year, driving t...
Cintas reported a 10.9% revenue increase to $3.01 billion in Q1 fiscal 2027 and exceeded EPS expectations with $1.39 per share. Following this strong performance, investment firm Robert W. Baird raised its price target for Cintas to $222, implying a ...
Block & Leviton is investigating Endava plc for potential violations of federal securities laws related to its accounting practices. The investigation follows Endava's announcement that CFO Mark Thurston was placed on administrative leave amid scruti...
